Studies aimed to decrease AChE activity with a potent AChE inhibitor to be developed, and in this way increase in ACh concentration in the synapse which would lead to increased cholinergic transmission and hence diminish AD symptoms. This evidence concerns the gene ACHE and Alzheimer disease.